Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Novartis : Shares Lifted by Prospect of Gilenya Exclusivity in US -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
07/12/2018 | 06:53pm CEST

By Donato Paolo Mancini

Novartis AG's (NOVN.EB) closed higher on Thursday after jumping on news of a ruling that suggested that market exclusivity for the company's multiple-sclerosis blockbuster drug Gilenya in the U.S. will likely be extended.

"A favorable resolution of the dosage regimen patent litigation" may lengthen the period in which the drug is free from generic competition, according to a Novartis document seen by Dow Jones Newswires.

The note was sent out at around midday Thursday, two analysts told Dow Jones, and shares started climbing around that time. One of the analysts said the market wasn't expecting the decision, so that sent the share price up.

According to the document, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office issued a decision upholding the validity of the dosage-regimen patent on Wednesday. The decision can be appealed, the document said.

Gilenya had sales of $3.19 billion in 2017, according to the company's annual report.

Novartis said it was pleased with the decision, and that it expected to maintain exclusivity until August 2019.

Shares closed up 4.1% at CHF78.94.

Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
07:14aNOVARTIS : Factory to close as Novartis cuts over 2,000 jobs
01:15aMHEALTH APP MARKET EXPECTED TO GROW : This market research report on MHealth Ap..
09/25NOVARTIS : Announces Five Grant Recipients of Excellence in Ophthalmology Vision..
09/25NOVARTIS : to Cut 2,000 Jobs Amid Revamp -- 2nd Update
09/25NOVARTIS : Sandoz receives positive CHMP opinion for proposed biosimilar pegfilg..
09/25SPARK THERAPEUTICS : Novartis announces positive CHMP opinion for one-time gene ..
09/25NOVARTIS : receives positive CHMP opinion for Gilenya for the treatment of child..
09/25NOVARTIS : Cuts Over 2,000 Jobs in Switzerland as It Continues to Refocus -- Upd..
09/25NOVARTIS : Plans to Cut Over 2,000 Jobs in Switzerland
09/25NOVARTIS : Plans to Cut Over 2,000 Jobs in Switzerland
More news
News from SeekingAlpha
09/25Pfizer facing difficult path to ramp up biosimilar business 
09/25CATALYST WATCH : Adamis Faces A Big FDA Decision This Week On Symjepi Jr. 
09/25Novartis to cut 2,000 jobs in restructuring; shares up 1% 
09/25ARVINAS IPO : 40% Is Cash, But Research Is At An Early Stage 
09/24Express Scripts taking credit for Gilead's planned launch of generic HCV meds 
Financials ($)
Sales 2018 52 459 M
EBIT 2018 12 888 M
Net income 2018 11 683 M
Debt 2018 14 565 M
Yield 2018 3,43%
P/E ratio 2018 14,84
P/E ratio 2019 21,09
EV / Sales 2018 4,47x
EV / Sales 2019 4,31x
Capitalization 220 B
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 91,5 $
Spread / Average Target 6,1%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-0.63%219 947
JOHNSON & JOHNSON2.26%376 847
PFIZER20.90%257 522
ROCHE HOLDING LTD.-5.48%209 212
MERCK AND COMPANY25.79%188 241
AMGEN17.94%134 121